Don’t send a generic resume — generate a resume and cover letter tailored to this exact role.
Monte Rosa Therapeutics, a clinical-stage biotech, is seeking a Manager, Data Management to oversee data management across trials. You will collaborate with Clinical Operations, Biostats, Programming, Medical, Safety, Regulatory, CROs, and vendors to ensure inspection-ready data.
This hands-on role requires experience with EDC systems (Medidata Rave or similar), data standards (CDISC/SDTM), and strong project leadership in oncology-focused studies.
The Manager, Data Management will be responsible for overseeing clinical data management activities across one or more clinical programs. This individual will work closely with Clinical Operations, Biostats and Programming, Medical, Safety, Regulatory, external CROs, and technology vendors to ensure high-quality, inspection-ready clinical data.
This is a hands-on role well suited for someone who thrives in a small biotech environment, can manage external partners effectively, and is comfortable moving between strategy, execution, and problem-solving.
Monte Rosa Therapeutics (MRT) is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond, and has a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug.